Autolus Exceeds Expectations with AUCATZYL Sales and Expansion

Autolus Therapeutics reported strong sales of AUCATZYL, exceeding initial expectations, with over 60 treatment centers operational in the US. The company anticipates net product revenue of $75 million for FY2025, marking the first year of commercial sales. AUCATZYL has also received regulatory approval in the UK and EU, with NHS commissioning under routine guidelines. The company plans to release its Q4 and full-year 2025 financial results in March 2026.